The Faculty of 1000 is a Web-based literature awareness tool published by BioMed Central. It provides a continuously updated insider's guide to the most important peer-reviewed papers within a range of research fields, based on the recommendations of a faculty of more than 1,400 leading researchers. Each issue, The Scientist publishes a review, like the one above, that examines related papers in a single field. We also publish a selection of comments on interesting recent papers from the Faculty

The Faculty of 1000 is a Web-based literature awareness tool published by BioMed Central. It provides a continuously updated insider's guide to the most important peer-reviewed papers within a range of research fields, based on the recommendations of a faculty of more than 1,400 leading researchers. Each issue, The Scientist publishes a review, like the one above, that examines related papers in a single field. We also publish a selection of comments on interesting recent papers from the Faculty

Although targeting angiogenesis is a promising anticancer approach, the recent spate of Phase III trial failures has bashed some scientists' hopes for success. According to industry insiders, however, the 12 recent failures involving five trials are symptoms of a young field, of clinical trial design that requires unconventional endpoints, and of improper delivery systems, rather than a condemnation of the general approach. Moreover, because drug development takes such a long time, researchers h

A three-alarm fire ravaged two labs at University of California, Santa Cruz, knocking out power and shutting down multiple buildings during the early hours of Jan. 11. The Sinsheimer building where the fire occurred remains closed, displacing approximately 150 researchers who are now scrambling to assess the damage, find new lab space, and salvage whatever is possible. "The upper floor, where the real devastation occurred, is not likely to be back to normal use for six to eight months," says Eli